NAT2‐poor metabolizer genotypes have been associated with increased circulating hydralazine concentrations, with subsequent effects on antihypertensive response, vasodilation, tachycardia, and potentially drug‐induced systemic lupus erythematosus (SLE).8 This evidence concerns the gene NAT2 and systemic lupus erythematosus.